Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
Mark Crowther, Distinguished University Professor and Chair, Department of Medicine at McMaster University, shared on LinkedIn:
”McMaster’s Department of Medicine: New Insight into a Life-Threatening Blood Disorder, Led by McMaster Researchers
A paper published last week in the New England Journal of Medicine has reshaped how we understand heparin-induced thrombocytopenia (HIT)—a serious reaction to a widely used blood thinner.
Researchers from McMaster Faculty of Health Sciences and the McMaster University Department of Medicine have found that, contrary to decades of belief, a single monoclonal antibody is responsible for triggering HIT.
This key discovery suggests the condition is not a polyclonal immune response, as previously thought, but rather driven by one dominant antibody—an insight that could significantly improve diagnostic precision and lead to more targeted therapies.
The study was led by Dr. Ishac Nazy, PhD, Professor in the Department of Medicine and John G. Kelton Chair in Immunological Blood Disorders and and Dr Donald Arnold.
Their team includes investigators from the McMaster Platelet Immunology Laboratory and the Michael G. DeGroote Centre for Transfusion Research.
Dr. Nazy notes: ‘Our findings correct a long-standing misunderstanding of HIT and point toward more accurate and safer testing methods.’
This work underscores McMaster’s continued leadership in translational research—bringing molecular discoveries closer to clinical application.”
Find more insights here.
Stay updated on the emerging in the field of platelet disorders with Hemostasis Today.
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number